Access to Oncology Medicines Coalition - The Medicines Patent Pool

Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hepatocellular carcinoma

Intraoperative Radiotherapy

Cancer survivors' stories: An African perspective

ESMO 2022: Highlights, commentary and analysis

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

New era of early cancer detection blood tests on the horizon

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19